Market capitalization | $1.81b |
Enterprise Value | $2.91b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 13.23 |
EV/Sales (TTM) EV/Sales | 1.05 |
P/S ratio (TTM) P/S ratio | 0.65 |
P/B ratio (TTM) P/B ratio | 1.20 |
Revenue (TTM) Revenue | $2.77b |
EBIT (operating result TTM) EBIT | $-86.90m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
13 Analysts have issued a Fortrea forecast:
13 Analysts have issued a Fortrea forecast:
Sep '24 |
+/-
%
|
||
Revenue | 2,775 2,775 |
-
|
|
Gross Profit | 425 425 |
-
|
|
EBITDA | 1.50 1.50 |
-
|
EBIT (Operating Income) EBIT | -87 -87 |
-
|
Net Profit | -280 -280 |
-
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Head office | United States |
CEO | Thomas Pike |
Employees | 18,000 |
Founded | 2023 |
Website | fortrea.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.